<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076981</url>
  </required_header>
  <id_info>
    <org_study_id>2107-ABU-009-LM</org_study_id>
    <nct_id>NCT05076981</nct_id>
  </id_info>
  <brief_title>Progesterone Levels During Ovulation and Luteal Phase</brief_title>
  <official_title>Progesterone Levels During Ovulation and Luteal Phase in Spontaneous Natural Ovulatory Cycles vs Modified Natural Cycle. A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ART Fertility Clinics LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ART Fertility Clinics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natural cycles are evaluated during fertility treatments for different therapeutic options,&#xD;
      like insemination (IUI), time intercourse (TI) or frozen-thawed embryo transfers (FET). Two&#xD;
      possible protocols can be used for natural cycles, with or without hCG trigger. Usually,&#xD;
      studies including natural cycles consider both options as equivalent, not considering the&#xD;
      possible bias that the exogenous hCG (human chorionic gonadotrophin) might have. In this&#xD;
      prospective study, Investigators aim to evaluate the differences in the hormonal profile&#xD;
      during the ovulation when it occurs spontaneously vs triggered with a bolus of hCG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the pure natural cycle (PNC), ovulation will be detected by a combination of ultrasound&#xD;
      monitoring the follicular growth and serial measurement of luteinizing hormone (LH),&#xD;
      estradiol (E2) and progesterone (P4) levels, which is recognised to be the most accurate&#xD;
      method of correctly identifying ovulation.&#xD;
&#xD;
      For the modified natural cycle (MNC), a bolus of rhCG 6500 IU subcutaneous (sc) will be&#xD;
      administered when 1 dominant follicle reaches 17mm or above, after excluding previous LH&#xD;
      surge. This is the first prospective study where the differences on the hormonal profile for&#xD;
      ovulation will be studied.&#xD;
&#xD;
      HYPOTHESIS:&#xD;
&#xD;
      H0: The hormonal profile is not different between the PNC and the MNC H1: The hormonal&#xD;
      profile is different between the PNC and MNC&#xD;
&#xD;
      Administration of hCG is a popular method for triggering ovulation since it may avoid the&#xD;
      need to perform IUI or FET at weekends. However, it is an intervention compared with the&#xD;
      detection of the spontaneous LH rise. Moreover, due to the presence of hCG receptors in the&#xD;
      human endometrium, administration of hCG might interfere with endometrial receptivity.&#xD;
      Previous publications evaluating pregnancy rates demonstrated that the use of hCG injection&#xD;
      during the natural cycle reduces the pregnancy rates, in FET and IUI. It remains unclear what&#xD;
      might be the mechanism to explain the lower pregnancy rates: a possible direct effect of hCG&#xD;
      on the hCG receptors of the endometrium or a modification of the hormonal profile after the&#xD;
      administration of the hCG, affecting the window of implantation (WOI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in hormone levels</measure>
    <time_frame>35 days</time_frame>
    <description>Small sample data will be analyzed with the use of non-parametric test like Wilcoxon test to a paired a test of difference in hormones levels of the patients represented in both cycles (PNC and MNC) (dependent samples). This test will be preferred due to non-independent interval or ratio data in addition not to meet the normality or homogeneity of variances assumptions as paired t-test.&#xD;
Hormonal pattern over the days (measured for some days during cycle 1 and cycle 2) will be analyzed using trend analysis (line fit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of visits in luteal phase</measure>
    <time_frame>17 days</time_frame>
    <description>Number of visits will be analyzed. The differences will be analyzed across PNC and MNC with CI. Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteal phase length</measure>
    <time_frame>17 days</time_frame>
    <description>Luteal phase length will be analyzed. The differences will be analyzed across PNC and MNC with CI. Fisher's exact test.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Pure Natural Cycle</arm_group_label>
    <description>Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)&#xD;
TVUS day 9-10 of cycle to identify dominant follicle.&#xD;
Blood test for IVF1 every 24h until identification of the LH surge.&#xD;
The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010).&#xD;
Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days.&#xD;
During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Natural Cycle</arm_group_label>
    <description>Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)&#xD;
TVUS day 9-10 of cycle to identify dominant follicle.&#xD;
Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration.&#xD;
IVF1 2h after rhCG.&#xD;
IVF1 every 12h for 2 days after rhCG.&#xD;
During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously</description>
    <arm_group_label>Modified Natural Cycle</arm_group_label>
    <other_name>Ovitrelle</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        healthy women with spontaneous ovulation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women below 40 years&#xD;
&#xD;
          -  Regular and Ovulatory cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous adnexal surgery&#xD;
&#xD;
          -  Endometriosis&#xD;
&#xD;
          -  PCOs&#xD;
&#xD;
          -  Using hormonal contraception during the previous 2 months: OCP, progesterone IUD&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>healthy women with spontaneous ovulation</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURA MELADO, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ART Fertility Clinics LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BARBARA LAWRENZ, PhD</last_name>
    <phone>026528000</phone>
    <phone_ext>1108</phone_ext>
    <email>barbara.lawrenz@artfertilityclinics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SHIERYL DIGMA, RN</last_name>
    <phone>026528000</phone>
    <phone_ext>1122</phone_ext>
    <email>shieryl.digma@artfertilityclinics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ART Fertility Clinics LLC</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>60202</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1108</phone_ext>
      <email>shieryl.digma@artfertilityclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Shieryl Digma, RN</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1122</phone_ext>
      <email>shieryl.digma@artfertilityclinics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Melado, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://vanbelle.org/presentations/CHSTalkNoPictures.pdf</url>
    <description>van Belle, G. (2002). Statistical rules of thumb. New York: John Wiley</description>
  </link>
  <link>
    <url>https://doi.org/10.1002/pst.185</url>
    <description>Julious, S. A. (2005). Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics, 4, 287-291</description>
  </link>
  <reference>
    <citation>Licht P, Fluhr H, Neuwinger J, Wallwiener D, Wildt L. Is human chorionic gonadotropin directly involved in the regulation of human implantation? Mol Cell Endocrinol. 2007 Apr 15;269(1-2):85-92. Epub 2007 Feb 14. Review.</citation>
    <PMID>17367920</PMID>
  </reference>
  <reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </reference>
  <reference>
    <citation>Kyrou D, Kolibianakis EM, Fatemi HM, Grimbizis GF, Theodoridis TD, Camus M, Tournaye H, Tarlatzis BC, Devroey P. Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study. Reprod Biomed Online. 2012 Sep;25(3):278-83. doi: 10.1016/j.rbmo.2012.05.005. Epub 2012 May 23.</citation>
    <PMID>22796236</PMID>
  </reference>
  <reference>
    <citation>Connelly LM. Pilot studies. Medsurg Nurs. 2008 Dec;17(6):411-2. Review.</citation>
    <PMID>19248407</PMID>
  </reference>
  <reference>
    <citation>Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247. Review.</citation>
    <PMID>18183564</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ART Fertility Clinics LLC</investigator_affiliation>
    <investigator_full_name>Laura Melado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>luteal phase</keyword>
  <keyword>natural cycle</keyword>
  <keyword>human chorionic gonadotropin</keyword>
  <keyword>progesterone</keyword>
  <keyword>progesterone rise</keyword>
  <keyword>ovulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

